Reply to the Editor  by Mangano, Dennis T.
Reply to the Editor:
My colleagues and I thank Dr Katz for his
letter. Please find below our responses to
his questions.
First, regarding the morphine-sparing
effect, we believe that this not only is sta-
tistically significant but clinically meaning-
ful for these patients. As you may be
aware, patients undergoing coronary artery
bypass grafting have impaired pulmonary
function, with most having a protracted
smoking history and an increasing number
having ventricular dysfunction. Contribut-
ing as well are the effects of narcotics,
particularly when administered early (12
hours)—that is, at about the time of tra-
cheal extubation. Thus we believe that
morphine-sparring provided by the cyclo-
oxygenase 2 inhibitors parecoxib and
valdecoxib is clinically relevant and should
not just be evaluated with patient comfort
indices, as one might for less severe sur-
gery in healthier patients.
Second, we also believe that the avoid-
ance of morphine-associated physiologic
effects is more important here than possible
effects on nausea, vomiting, dizziness, se-
dation, fatigue, and constipation. Please
note that in our patients these patient com-
fort measures are affected not only by the
pain reliever administered, but also—and
more profoundly—by the effects of ex-
treme reperfusion, hypothermia, and the in-
herent cytotoxic responses affecting the
end-organs with which you have concern:
the brain (sedation, dizziness), the gut
(nausea, vomiting), and the skeletal mus-
cles and metabolism (fatigue). Generally,
then, any analyses, as I believe you sug-
gest, will be heavily confounded by these
factors in these patients.
Third, I respectfully disagree with your
comments regarding “interpretable pain
data.” We believe that reporting peak pain
intensity difference, calculated for each
day of treatment and with a baseline con-
trol, and our measures of patient and phy-
sician global assessment, are sensitive
measures, are interpretable, and are mean-
ingful. For example, regarding the clinical
relevance of a 1-unit finding on a 4-unit
pain intensity scale, we believe that this is
substantive, especially when considering
that the control group was designed to be
aggressively treated well in excess of that
usually practiced. This design was specifi-
cally chosen to be conservative, therefore
imposing a higher standard for these new
pain relievers.
Finally, and importantly, regarding
safety, we too believe that our findings
regarding infection and inflammation raise
serious concerns. We, however, believe
that analysis of historical data of similar
populations as the placebo group may re-
veal important insights. We are assured (by
the sponsor) that such analyses will be pur-
sued in the near future, and we are com-
mitted to performing those analyses inde-
pendently. Therefore, I reserve response to
this important question which you raised
until we have performed such analyses.
Those results will be given in a second
response letter to this Journal, and my
group will await your comments after that
publication.
Dennis T. Mangano, PhD, MD
Ischemia Research and Education Foundation
San Francisco, CA 94121
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Heterotopic right heart
transplantation
To the Editor:
In a recent issue of the Journal, Elefteri-
ades and coworkers1 published their inter-
esting short-term experimental study with
the technique for isolated accessory right
heart transplantation. The idea is definitely
clever, and this technique will open new
potential approaches in the management of
patients with congenital heart defects.
According to the suggestions of the au-
thors, this technique should be taken into
consideration as a potential alternative
treatment in two groups of patients1: (1)
children with congenital heart defects and
right heart malformation not allowing a
biventricular type of repair because of the
presence of a right ventricle that is either
underdeveloped or malfunctioning and (2)
patients with congenital heart defects and
either right ventricular failure after biven-
tricular repair in the presence of elevated
pulmonary vascular resistance, or failure of
Fontan type of procedure because of the
presence of mild to moderate increase of
pulmonary vascular resistance.
Despite the authors’ acknowledgement
that cardiac surgeons will have to consider
this new technique as simply another tool
in their armamentarium to face complex
situations, it probably is worthwhile to con-
sider other options not discussed in this
article. For the patients of group 1, the
alternative of one-and-a-half ventricular re-
pair should be always ruled out before con-
sidering accessory right heart transplanta-
tion. In most children with complex
congenital heart defects, it is possible to
use a hypoplastic or malfunctioning right
ventricle to pump the inferior vena cava
venous return into the pulmonary circula-
tion, deviating the venous return from the
superior vena cava directly into the pulmo-
nary circulation with an end-to-side anas-
tomosis to the right pulmonary artery (bi-
directional Glenn). This approach of one-
and-a-half ventricular repair, which is of
course suitable only in the presence of nor-
mal pulmonary vascular resistance, has
been proved successful in various reported
experiences.2-4
For patients in group 2, with elevated
pulmonary vascular resistance, not suitable
for a Fontan type of procedure or with
failing Fontan procedure, the authors did
not provide any proof that their technique
with the two right ventricles will allow the
heart to overcome elevated pulmonary vas-
cular resistance. They did demonstrate that
the system with two right ventricles can
work in the short term, but they did not
provide any data regarding the possibility
for this combination with an unprepared
donor right ventricle of supporting either a
right ventricular volume overload or a pres-
sure overload.
At this point, if we have a donor heart
available and wish to consider a donor ven-
tricle to pump against elevated pulmonary
vascular resistance in heterotopic position,
we consider it much better to use a donor
left ventricle. A left ventricle is definitely
able to overcome very high pulmonary vas-
cular resistance, at least up to a systemic
level.
This idea was tested in an acute exper-
imental study performed when I was at
University of California, Los Angeles, and
we were able to prove that our heterotopic
right heart assist transplant (heart with two
left ventricles) was able to function against
pulmonary vascular resistance artificially
elevated to the systemic level.5 Although
this technique requires a little more com-
plicated surgical approach and understand-
ing, as the technique reported by Elefteri-
ades and coworkers1 does not require
cardiopulmonary bypass, it could poten-
tially applied to a much larger patient pop-
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